Added to YB: 2024-11-28
Pitch date: 2024-11-28
TMDX [bullish]
TransMedics Group, Inc.
+44.95%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.5B
Pitch Price
$87.47
Price Target
261.75 (+106%)
Dividend
N/A
EV/EBITDA
35.52
P/E
51.63
EV/Sales
7.99
Sector
Health Care Equipment and Supplies
Category
growth
Show full summary:
TransMedics: A Rare Opportunity to Buy High Growth at a Discount
TMDX: Strong Q3 revenue $108.8M (+64% YoY), net income $4.2M vs -$25.4M loss Q3 2023. 2024 guidance $425-445M (+76-84% YoY). Recent price drop to $85 from highs offers buying opportunity. 3X upside potential by end of 2025 despite Q3 miss.
Read full article (1 min)